Related Experiment Video
Updated: Jul 14, 2026
22:06
Induction and Monitoring of Adoptive Delayed-Type Hypersensitivity in Rats
Published on: October 1, 2007
Anticonvulsant hypersensitivity syndrome: identification and management
1Tricia Y. Ting, MD Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. tting@som.umaryland.edu.
Current Treatment Options in Neurology
|June 21, 2007
Summary
Anticonvulsant hypersensitivity syndrome is a severe drug reaction. Early drug withdrawal is key; intravenous immunoglobulin may aid recovery and be safer than corticosteroids.
Area of Science:
- Immunology
- Pharmacology
- Dermatology
Background:
- Anticonvulsant hypersensitivity syndrome (AHS) is a rare, severe, delayed-type immune reaction.
- Limited effective treatments exist beyond drug cessation.
- AHS carries a significant risk of mortality, particularly from sepsis with corticosteroid use.
Purpose of the Study:
- To review current understanding and management of AHS.
- To highlight the potential benefits and safety of intravenous immunoglobulin (IVIG).
- To emphasize preventative strategies through patient identification and counseling.
Main Methods:
- Review of existing uncontrolled studies on AHS treatment.
- Analysis of comparative risks between IVIG and systemic corticosteroids.
- Discussion of genetic and drug-specific factors in AHS susceptibility.
Main Results:
- Early recognition and drug discontinuation are critical for managing AHS.
- IVIG shows promise in hastening recovery and may be safer than corticosteroids.
- Corticosteroid therapy is associated with increased mortality risk due to sepsis.
Conclusions:
- Identifying patients at risk for AHS is crucial for prevention.
- Understanding drug cross-sensitivity and familial susceptibility aids in risk assessment.
- IVIG represents a potentially safer therapeutic option for AHS compared to corticosteroids.
Related Concept Videos
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:30Hypersensitivities
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
01:19Hypersensitivity Reactions: Immune-Complex Reactions
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...